Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28174120 | 0.74 | BRD4 (0.38) | CYP3A4TRPA1LMNAHTT | |
| SCHEMBL14648592 | 0.74 | ALDH1A1 (0.32) | CYP3A4TRPA1LMNAHTT | |
| SCHEMBL14470991 | 0.71 | ALDH1A1 (0.33) | CYP3A4LMNAHTT | |
| SCHEMBL9063324 | 0.69 | CYP3A4 (0.56) | CYP3A4CHRM1ALOX15MAOATBXA2R | |
| SCHEMBL19448946 | 0.69 | CA12 (0.43) | CYP3A4ALOX15LMNAHTT | |
| SCHEMBL1274930 | 0.68 | ALDH1A1 (0.38) | CYP3A4ALOX15TRPA1LMNAHTT | |
| SCHEMBL29577280 | 0.68 | ALDH1A1 (0.38) | CYP3A4ALOX15TRPA1LMNAHTT | |
| SCHEMBL6050007 | 0.68 | CYP3A4 (0.50) | CYP3A4ALOX15TRPA1LMNAHTT | |
| SCHEMBL11213752 | 0.68 | BRD4 (0.40) | CYP3A4ALOX15MAOAHTT | |
| SCHEMBL27850945 | 0.68 | CYP3A4 (0.35) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024455-A1 | COMPOUND WHICH INHIBITS TELOMERE-BINDING PROTEIN, AND TELOMERE-BINDING PROTEIN INHIBITOR CONTAINING SAME | HIROSHIMA UNIVERSITY (JP) | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024455-A1 | COMPOUND WHICH INHIBITS TELOMERE-BINDING PROTEIN, AND TELOMERE-BINDING PROTEIN INHIBITOR CONTAINING SAME | TERF2IP, TERF2, POT1 | CYP3A4 4592/4885CHRM1 4815/4885ALOX15 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.